

Executive Committee Call, 16 February 2018
Minutes

Attended:	Apologies:	Secretariat
Joanne Carter (Vice-Chair) Timur Abdullaev Erika Arthun Amy Bloom Megan Cain Paula Fujiwara Tereza Kasaeva Nalini Lachance Austin Obiefuna Aaron Oxley Victor Ramathesele Cheri Vincent		Lucica Ditiu Jenniffer Dietrich Jacqueline Huh Greagory Paton Catie Rosado
Minutes of Discussion		Outcome(s)
1. 30th Board Meeting in New Delhi		
<p>The Executive Director presented the agenda of the Board meeting for 14-15 March 2018, as well as details of the site visits for Board participants on 12 March. The Coordinating Group on the UNHLM on TB will meet in the afternoon of 12 March (in-person & call-in). A big event is being organized in partnership with the government of India, where the Prime Minister of India will give a keynote address about TB on 13 March in the morning. Seven ministers of health from the Southeast Asian Region plus eight ministers invited by Stop TB will be part of the meeting in the afternoon of 13 March. The Executive Director travels to New Delhi next week for the Vaccines Forum and will have time to meet with government authorities.</p> <p>Executive Committee members discussed with the Secretariat several points around the agenda timings and content, as well as the Financing Dialogue panel.</p> <p>Furthermore, the Executive Director touched upon the last session of the Board meeting which decides on the venues for the next Board meeting. Three options were presented as potential venues: Tokyo, London, Geneva. Although Geneva seems to be the better option at the moment, the Executive Committee requested more time for consideration and a document outlining the points to consider in order to make a decision.</p>		<ul style="list-style-type: none"> • Executive Committee members should share in writing with the Secretariat any decision points or outcomes expected from the Board sessions. • Executive Committee requested the Secretariat to prepare a comparative table about the options for venues of the next Board meeting.
2. Governance		
<p>a. Review of the Governance Manual: The Governance Manual version shared with the Executive Committee in advance of the call the version with Canada’s edits and comments. Some comments will need a further in-depth discussion, which will be discussed</p>		<ul style="list-style-type: none"> • The Executive Committee endorsed to move forward the

<p>later on during another round of reviews. The Governance Manual is a 'living document'.</p> <p>One member of the Executive Committee asked to be able to get back with additional comments that week.</p> <p>In general, the Executive Committee is pleased with the Governance Manual and if there are no substantial changes, the Committee requests to present this version for approval from the Board before making it publicly available.</p> <p>b. Flexible Seats of the Executive Committee:</p> <p>Three eligible constituencies expressed their interest to be part of the Executive Committee, and committed their board member's time:</p> <ol style="list-style-type: none"> a. Developed Country NGOs, Aaron Oxley b. Developing Country NGOs, Austin Obiefuna c. New Tools Working Group, David Lewinsohn <p>However, only two seats are available for these constituencies. Without wanting to set a precedent, the Developed Country NGOs and Developing Country NGOs constituencies offered to jointly share one flexible seat of the Executive Committee. Each constituency representatives spoke to explain the proposal.</p> <p>As a result, the Executive Committee accepted that both constituencies share a flexible seat and appointed the second flexible seat of the Executive Committee to the Research Working Group constituency.</p> <p>c. Private Sector Constituency:</p> <p>The Secretariat was informed about the fact that Dr Robert Newman, Private Sector constituency representative, is not working for Johnson&Johnson anymore. In line with the Governance Manual, the action to follow is the same process that put the board member in place initially. This means that the Private Sector constituency needs to decide which of the following options they would like to pursue:</p> <ol style="list-style-type: none"> a. Ask Johnson&Johnson to replace Dr Newman with someone else from the company to serve until the end of the term. b. Initiate an entire new process with public announcement, selection procedure, endorsement by the Executive Committee and approval by the Board. 	<p>Governance Manual for approval by the Board with the caveat that certain issues will be determined later.</p> <ul style="list-style-type: none"> • Both flexible seats of the Executive Committee were selected and their names will be transmitted for electronic approval by the Board.
<p>3. AOB</p>	
<p>Next Executive Committee Conference Call is scheduled for 5 March 2018.</p>	<ul style="list-style-type: none"> • Stop TB Secretariat to send out calendar invite.